Chief Executive Officer · Virpax Pharmaceuticals, Inc. (VRPX)

Gerald Bruce

FY2023 is the first fiscal year CompBrief holds for Gerald Bruce as a named executive officer of Virpax Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$128,000

Salary $38,000Stock awards $0Bonus $29,000

5th of 5 named executive officers at Virpax Pharmaceuticals by FY2023 total.

5 named officers on file for Virpax Pharmaceuticals, FY2023

Gerald Bruce’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Virpax Pharmaceuticals’s whole pay program stands against its peers

  • Virpax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRPX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 12, 2024 (10-K).

Free

Get Gerald Bruce’s full pay file as a PDF — free

More than this page: up to 10 years of Gerald’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gerald Bruce compensation by year

Virpax Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Virpax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$38,000
Bonus$29,000
Stock awards$0
Option awards$61,000
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$128,000

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Virpax Pharmaceuticals, Inc. 10-K filed June 12, 2024, accession 0001213900-24-052146, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Virpax Pharmaceuticals, Inc. filed document, accession 0001213900-24-052146. Every figure is read from that document and cited to the page and table it appears in. Filed June 12, 2024.

Virpax Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anthony MackFormer Chief Executive Officer, Chairman (3)$1,216,000
Sheila MathiasChief Scientific Officer$498,000
Christopher ChipmanFormer Chief Financial Officer (5)$491,000
Vinay ShahChief Financial Officer$324,000
Gerald Bruce · this pageChief Executive Officer$128,000

Board service

Virpax Pharmaceuticals board · FY2023

How this board is paid

Company policy: Virpax Pharmaceuticals pays directors a $60,000 cash retainer. As stated in Virpax Pharmaceuticals's FY2023 proxy.

The full Virpax Pharmaceuticals compensation record

free company brief

This page is one person within Virpax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Virpax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gerald Bruce's compensation dossier · One-time report. No refunds.